Quinoline derivatives as nk3 antagonists

Details Quinoline derivatives as nk3 antagonists Quinoline derivatives as nk3 antagonists

A - Human Necessities

61

K

A61K 31/47 (2006.01) A61P 25/18 (2006.01) C07D 215/52 (2006.01) C07D 221/18 (2006.01) C07D 401/04 (2006.01) C07D 401/12 (2006.01) C07D 405/04 (2006.01) C07D 409/04 (2006.01) C07D 409/12 (2006.01) C07D 417/04 (2006.01)

Patent

CA 2238171

A method for the treatment and/or prophylaxis of conditions characterized by overstimulation of the tachykinin receptors, which method comprises the administration to a mammal in need thereof of an effective, non-toxic, pharmaceutically acceptable amount of a compound of formula (I), or a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable salt thereof, wherein: Ar is an optionally substituted phenyl, naphthyl or C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, O, N; R is linear or branched C1-8alkyl, C3-7cycloalkyl, C4-7cycloalkylalkyl, optionally substituted phenyl or phenyl C1.6alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N. hydroxy C1-6alkyl, amino C1- 6alkyl, C1-6alkylaminoalkyl, di C1-6alkylaminoalkyl, C1-6acylaminoalkkyl, C1- 6alkoxyalkyl, C1-6alkylcarbonyl, carboxy, C1-6alkoxycarbonyl, C1-6alkoxycarbonyl, C1-6alkyl, aminocarbonyl, C1-6alkylaminocarbonyl, di C1- 6alkylaminocarbonyl; halogeno C1-6alkyl; or is a group - (CH2)p- when cyclized onto Ar, where p is 2 or 3, R1 and R2, which may be the same or different, are independently hydrogen or C1-6 linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3, 4 or 5; or R1 together with R1 forms a group -(CH2)q-, in which q is 2, 3, 4 or 5: R3 and R4, which may be the same or different, are independently hydrogen, C1-6 linear or branched alkyl, C1.6alkenyl, aryl, C1-6alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C1-6alkylamino, -O(CH2)r-NT2, in which r is 2, 3 or 4 and T is hydrogen or C1-6alkyl or it forms with the adjacent nitrogen a group (a) or (b), in which V and V1 are independently hydrogen or oxygen and u is 0, 1 or 2; -O(CH2)s-OW in which s is 2, 3 or 4 and W is hydrogen or C1-6alkyl; hydroxyalkyl, aminoalkyl, mono- or di-alkylaminoalkyl, acylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group -(CH2)t- when cyclized onto R5 as aryl, in which t is 1, 2 or 3; R5 is branched or linear C1-6alkyl, C3acycloalkyl, C4- 7cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, O, N; X is O, S, or N-C=N.

Affiliated with

Also associated with

Rating

Quinoline derivatives as nk3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoline derivatives as nk3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives as nk3 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1827639